GLP-1 Patient Intake Form Template

A comprehensive patient intake form is the foundation of any safe and compliant GLP-1 weight loss program. This template covers the essential clinical, demographic, and screening information providers need before prescribing semaglutide, tirzepatide, or other GLP-1 receptor agonists. Designed for primary care practices, weight loss clinics, and med spas adding cash-pay GLP-1 programs, this form includes BMI documentation, cardiovascular risk screening, medication reconciliation, and contraindication checks required by clinical guidelines. Every section is aligned with current FDA labeling requirements and AACE/ACE obesity management recommendations.

Form Preview

GLP-1 Patient Intake Form | Your Practice Name
Preview

Section 1 of 6

Patient Demographics

Please provide your contact and basic information.

Full Name *

Jane Smith

Date of Birth *

...

Biological Sex *

Female

Phone Number *

(555) 000-0000

Email Address *

[email protected]

Emergency Contact Name & Phone *

...

Section 2 of 6

Weight & BMI

Your current measurements help us determine the right program for you.

Current Weight (lbs) *

185

Height *

5'6"

Goal Weight (lbs)

155

Highest Adult Weight (lbs)

210

Previous Weight Loss Attempts

Diet, exercise, medications tried...

Section 3 of 6

Medical History

Please check any conditions you have or have had.

Current Medical Conditions

Do any of the following apply to you?

Previous Surgeries

List any previous surgeries and approximate dates

Known Allergies *

Medications, foods, environmental allergies

Are you allergic to any of the following?

Section 4 of 6

Current Medications

Please list everything you're currently taking.

Current Medications *

List all current medications, dosages, and frequency

Current Supplements

Vitamins, herbal supplements, OTC medications

Are you currently taking insulin or sulfonylureas?

Section 5 of 6

Lifestyle & Goals

Help your provider personalize your treatment plan.

Smoking / Tobacco Status *

Never

Alcohol Use *

None

Primary Weight Loss Goal *

Improve overall health

Exercise Frequency *

Sedentary (little to no exercise)

Dietary Preferences or Restrictions

Vegetarian, keto, food allergies, etc.

Section 6 of 6

Referral & Payment

A few final details to get started.

How did you hear about this program?

Doctor referral

Primary Care Physician Name

...

Payment Method *

Credit/Debit Card

This is a preview. Actual form will be customized with your practice branding.

Compliance & Regulatory Notes

GLP-1 receptor agonists carry an FDA boxed warning regarding thyroid C-cell tumors observed in rodent studies. All intake forms must screen for personal or family history of medullary thyroid carcinoma (MTC) and MEN 2 syndrome. See FDA labeling: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf

BMI eligibility criteria for GLP-1 weight management follow FDA-approved indications: BMI >= 30 kg/m2, or BMI >= 27 kg/m2 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia).

Medication reconciliation should flag concurrent use of insulin or sulfonylureas, which may require dose adjustment to reduce hypoglycemia risk when initiating GLP-1 therapy.

Practices using compounded semaglutide must comply with applicable state pharmacy board regulations and FDA guidance on 503A/503B compounding. See FDA compounding guidance: https://www.fda.gov/drugs/human-drug-compounding

Patient intake data must be stored and transmitted in compliance with HIPAA Privacy and Security Rules (45 CFR Parts 160 and 164). See HHS HIPAA guidance: https://www.hhs.gov/hipaa/index.html

Want This Form Automated?

Karpa Health turns static intake forms into a fully automated clinical workflow.

  • Branded patient intake embedded on your website
  • AI clinical review with contraindication screening
  • One-click prescribing to compounding pharmacies
  • Automated follow-up and refill management
  • E-signatures, HIPAA compliance, and audit trail
Book a Demo

Related Clinical Forms

Sources & References

  1. FDA Prescribing Information for Semaglutide (Wegovy)
  2. AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity
  3. FDA Guidance on Drug Compounding
  4. HHS HIPAA Privacy and Security Rules

Frequently Asked Questions

What should a GLP-1 patient intake form include?

A GLP-1 intake form should capture patient demographics, BMI/weight history, medical history (including contraindication screening for MTC and MEN 2), current medications, allergies, lifestyle factors, and payment information for cash-pay programs. The form must screen for FDA-listed contraindications before prescribing.

Is a separate intake form needed for semaglutide vs. tirzepatide?

The core intake form can be used for both semaglutide and tirzepatide programs, as the contraindication screening and medical history requirements are similar. However, separate consent forms may be appropriate since tirzepatide has a distinct mechanism of action (dual GIP/GLP-1 agonist).

Do I need a different form for compounded vs. brand-name GLP-1 medications?

The intake form is the same regardless of medication source. However, if you are prescribing compounded semaglutide, you should add a consent disclosure explaining the compounded nature of the medication and that it is not FDA-approved in its compounded form. A separate consent form is recommended.

Can I use this intake form for telehealth GLP-1 consultations?

Yes, this form works for both in-person and telehealth consultations. For telehealth, you should also collect a telehealth-specific consent form covering technology requirements, privacy, and state-specific telehealth prescribing regulations.

How often should GLP-1 patient intake forms be updated?

Review and update your intake forms at least annually, or whenever FDA labeling changes, state regulations are updated, or your program adds new medications. Track regulatory changes through FDA MedWatch and your state medical board.